Finally, activity on patients’ samples was evaluated. Bone marrow cells were obtained from a Ph-negative MDS/MPN with neutrophilia, a Ph+ CML carrying the native fusion protein, and two Ph+ ...
Bcr-Abl transformation leads to chronic myeloid leukemia (CML). The acquirement of T315I mutation causes tyrosine kinase inhibitors (TKI) resistance. This study develops a compound, JMF4073, ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid ...
Enliven Therapeutics (ELVN) added nearly 20% in the premarket on Thursday after the cancer drug developer posted updated results from a Phase 1 trial for its lead candidate ELVN-001 in patients with ...
A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do not simply block cancer proteins but rather shut down the "protein ...
Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...
Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. By way of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results